Our enhanced medMATCH® report provides actionable insights and “at-a-glance” interpretation. Below you’ll find resources highlighting the features of the report, information about our test panels and recent test code changes, and an explanation of our simplified ordering process.
The following resources are provided to assist patients in completing at-home or self-collection of lab samples for physician-ordered drug monitoring tests. The resources include an instruction guide and demonstration video for oral fluid self-collection, and an instruction guide for urine specimen self-collection.
The COVID-19 pandemic presents some difficult challenges to providing appropriate levels of drug monitoring for opioids and other prescription drugs. Below are some resources we hope will be helpful.
Drug Misuse in America 2021: Physician Perspectives and Diagnostic Insights on the Drug Crisis and COVID-19, a Quest Diagnostics Health Trends report, explores the impact of the pandemic on drug misuse using nearly 5 million deidentified laboratory tests performed by Quest Diagnostics from 2011 through 2020 for patients in all 50 states and the District of Columbia.
The report is believed to be the first of its kind that juxtaposes laboratory test results with findings from an online survey of 505 US primary care physicians about the use of controlled prescription medications and illicit drugs in the United States during the COVID-19 pandemic.
To better understand the relationship between the COVID-19 pandemic and the drug misuse epidemic in the US, Quest Diagnostics study investigators analyzed changes in drug positivity rates and drug testing volumes, utilizing deidentified urine drug testing (UDT) results from January 1, 2019 to May 16, 2020.
Study results show that prescription drug monitoring declined during the weeks of the COVID-19 pandemic studied, while positivity for nonprescribed illicit drugs and dangerous drug combinations increased.
Drug Misuse in America 2019: Physician Perspectives and Diagnostic Insights on the Evolving Drug Crisis, a Quest Diagnostics Health Trends™ report, presents findings from analysis of more than 4.4 million de-identified aggregated clinical drug monitoring tests performed by Quest Diagnostics for patients from all 50 states and District of Columbia from 2011 through 2018.
A collaboration between the Center on Addiction and Quest Diagnostics, this report may be the first of its kind, juxtaposing an analysis of more than 4.4 million de-identified clinical drug monitoring tests by Quest Diagnostics and a survey conducted by The Harris Poll of 500 primary care physicians about their patients’ use of controlled substances.
As an industry leader in drug testing, Quest Diagnostics provides a wealth of information and resources to help you make more informed decisions for your patients.
Browse our webinar library for a series of presentations by leading medical experts at Quest Diagnostics.